COMMUNIQUÉS West-GlobeNewswire

ACTG Presents Study at CROI Elucidating Mechanism of CMV on Aging-Related Pathways in HIV
04/03/2024
LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented the poster “Suppressing Asymptomatic CMV with Letermovir Reshapes [...]
Vaxil Bio Proposed Reverse Takeover with Copper Bullet Terminated and Update of Research Activities
04/03/2024
Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States NESS-ZIONA, Israel, March 04, [...]
Novo Nordisk A/S - share repurchase programme
04/03/2024
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 04 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the [...]
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
04/03/2024
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral [...]
Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
04/03/2024
US Army Medical Research and Development Command Vendor Day Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced [...]
NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage
04/03/2024
CARMEL, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates
04/03/2024
Redesigned website reflects the Company's expanded pipeline of non-opioid pain management products and links to its recent publications and news PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding [...]
Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting
04/03/2024
– Late-breaking oral presentation to highlight efficacy and safety of ESK-001 in a Phase 2 clinical trial and open label extension (OLE) study in adults with moderate-to-severe plaque psoriasis (STRIDE) – – Additional [...]
Intelligent Scopes Launches Helga AI-GEP™, an AI Platform for Gastroenterology with the Commencement of Validation of its AI Software Tool for Colon Cancer
04/03/2024
NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp , specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to [...]
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
04/03/2024
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for Menkes disease Cyprium Therapeutics, a majority-owned subsidiary [...]
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
04/03/2024
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose by the End of 2025 [...]
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
04/03/2024
JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received notice from The NASDAQ [...]
NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
04/03/2024
LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
04/03/2024
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topline data H2 2024 UK [...]
Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting
04/03/2024
SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, is excited to announce its [...]
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
04/03/2024
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference [...]
Safety Shot Appoints Serial Entrepreneur John Gulyas as Chairman of the Board
04/03/2024
With multiple 7-figure exits, John Gulyas will help lead Safety Shot in its ongoing efforts to become a leading wellness beverage brand. JUPITER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) ( [...]
Invitation to Participate in STOP-PC Clinical Trial
04/03/2024
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional information can be [...]
Molecular Templates, Inc. Provides Interim Update
04/03/2024
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- [...]

Pages